Treatment of pediatric non-Hodgkin lymphoma in Hungary: 15 years experience with NHL-BFM 90 and 95 protocols

dc.contributor.author	Müller, Judit
dc.contributor.author	Csóka, Monika
dc.contributor.author	Jakab, Zsuzsanna
dc.contributor.author	Ponyi, Andrea
dc.contributor.author	Erlaky, Hajna
dc.contributor.author	Kovács, Gábor
dc.date.accessioned	2017-05-12T08:29:28Z
dc.date.available	2017-05-12T08:29:28Z
dc.date.issued	2008
dc.identifier	38549146384
dc.identifier.citation	pagination=633-635; journalVolume=50; journalIssueNumber=3; journalTitle=PEDIATRIC BLOOD & CANCER;
dc.identifier.uri	http://repo.lib.semmelweis.hu//handle/123456789/4205
dc.identifier.uri	doi:10.1002/pbc.21144
dc.description.abstract	Retrospective analysis was performed to assess the survival-rates of children with non-Hodgkin lymphoma (NHL), treated according to the NHL-BFM (Berlin-Frankfurt-Munster)-90 and -95 protocols between 1990 and 2004 in Hungary, and to compare our data with the international results. Ninety-one patients had non-B-NHL, 108 B-NHL, and 31 ALCL. Complete remission rate was 89%, while 12% relapsed later. The 5-year-overall-survival was 78% and the event-free survival was 75%. These results are lower than those reported by the BFM study group, but comparable from other European centers. In the last 5 years, the results showed 10% improvement and death during induction was reduced from 10 to 3%.
dc.relation.ispartof	urn:issn:1545-5009
dc.title	Treatment of pediatric non-Hodgkin lymphoma in Hungary: 15 years experience with NHL-BFM 90 and 95 protocols
dc.type	Journal Article
dc.date.updated	2017-03-31T09:37:16Z
dc.language.rfc3066	en
dc.identifier.mtmt	1633274
dc.identifier.wos	000252587300024
dc.identifier.pubmed	17366531
dc.contributor.department	SE/AOK/K/II. Sz. Gyermekgyógyászati Klinika
dc.contributor.institution	Semmelweis Egyetem